Abstract
A heart transplant 62-year-old patient referred for coronavirus-19 disease (COVID-19) pneumonia. At admission, he was febrile, tachypnoeic, and mild hypoxic with dry cough; during hospitalization, a diffuse morbilliform skin rash appeared. He was treated with tocilizumab with symptoms improvement, without a complete pulmonary function recovery. Skin rash, highly suggestive for COVID-19 cutaneous involvement, persisted for ten days despite tocilizumab administration.
Keywords:
COVID-19; heart transplant; pneumonia; tocilizumab.
© 2020 Wiley Periodicals LLC.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Anticoagulants / therapeutic use
-
COVID-19 / immunology
-
COVID-19 / physiopathology
-
COVID-19 Drug Treatment*
-
Cardiomyopathy, Dilated / complications
-
Cardiomyopathy, Dilated / surgery
-
Cough / physiopathology
-
Diarrhea / physiopathology
-
Enoxaparin / therapeutic use
-
Enzyme Inhibitors / therapeutic use
-
Exanthema / physiopathology
-
Fever / physiopathology
-
Glucocorticoids / therapeutic use
-
Heart Transplantation*
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Hypoxia / physiopathology
-
Immunocompromised Host / immunology
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Nausea / physiopathology
-
Piperacillin, Tazobactam Drug Combination / therapeutic use
-
Pulmonary Disease, Chronic Obstructive / complications
-
Renal Insufficiency, Chronic / complications
-
SARS-CoV-2
-
Tachypnea / physiopathology
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Enoxaparin
-
Enzyme Inhibitors
-
Glucocorticoids
-
Immunosuppressive Agents
-
Piperacillin, Tazobactam Drug Combination
-
Hydroxychloroquine
-
tocilizumab
-
Methylprednisolone